Business - Briefly   

USFDA nod for Strides Arcolab Bangalore facility

BANGALORE: Strides Arcolab has received approval from the U.S. FDA for its manufacturing site in Bangalore for oral dosage forms. The company informed the Bombay Stock Exchange that its manufacturing site in Bangalore, has been classified as `U.S. FDA compliant'. "The approval is an important milestone in the company's regulated market strategy. The fact that the facility was approved with No. FDA-483, clearly demonstrates the technical strength of the company," said Arun Kumar, Group CEO and Managing Director, Strides Arcolab.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

CCEA nod for PPP in infrastructure
VSNL to acquire Teleglobe
Auto testing centres plan approved
Apollo's mini-metros plan
SBI in talks with four banks
Maruti first quarter net profit up 32 p.c.
Idea Cellular's new offerings
Decision on PSUs boosts stock market prices
Rupee drops further
Exchange rates
Bullion rates
Exemption from BCTT
RBI optimism on economy
ICICI Bank ties up with Fortis
Exim Bank investment in SME
MSEB to be partner in DPC
Indian Bank takes possession of property
Coimbatore Productivity Council's office-bearers
IOB offers insurance cover to customers
Helios & Matheson announces 1:1 bonus
BHEL bags $100 m Indonesian contract
Uniply plans unit in Uttaranchal
Hispano bags contract for 800 buses
Course in steel technology
BEL net drops
Vijaya Bank Q1 net down 71 p.c.
USFDA nod for Strides Arcolab Bangalore facility

Copyright © 2005, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu